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Chapter-I                                                                                                                             General Introduction
                                                    INTRODUCTION
                      Drug discovery has its beginning in the root of mankind. Medicinal chemistry is a
science whose roots lie in all branches of chemistry and biology1.
                  The practice of medicinal chemistry is devoted to the discovery and development
of  new  agents  for  treating  disease2.  The  recent  advancement  like  drug  designing,
combinatorial  chemistry,  molecular  biology and  genetic  engineering  make interesting the
medicinal chemistry approach
 
3
.
                 Modern Drug Design, as compared with,” Let’s make a change on an existing
compound or synthesis a new structure and see what happen” is a fairly recent discipline still
in its infancy.
                Early Drug Design started with elucidation of the structure of the natural product,
followed  by  selective  changes  in  the  molecule.  The  later  was  done  for  many  reasons,
including the reduction of an undesirable pharmacological response (side effects), obtaining a
better pharmacokinetic response, altering the drug’s metabolism, securing a more plentiful,
less costly supply and producing a competing product2. 
               Once a new Pharmaceutical Lead Compound has been identified, extensive and
costly efforts usually are made to prepare a series of analogue in the hope that even better
activity will be found2.Medicinal  chemistry remains a challenging science which provides
profound satisfaction to its practioners4.
               Medicinal Chemists have a chance to participate in the fundamentals of prevention,
therapy and understanding of diseases and thereby contribute to a healthier and happier life5.
1
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                               QUINAZOLINONES- AN OUTLOOK
               Quinazoline is a fused bicycle compound earlier known as benzo 1, 3 diazine was 
first prepared in the laboratory by Gabriel in 1903 6, 55
N
N
quinazoline
               The name Quinazoline was first proposed for this compound by Weddige on 
observing that this was isomeric with the compounds cinnoline and Quinoxaline.
               Depending upon the position of the keto (or) oxo group, these compounds may be 
classified in to two types:
   1. 2-(1H) Quinazolinone
   2. 4-(3H) Quinazolinone
                                           
N
N
H
O
quinazolin-2(1H)-one
                                                
NH
N
O
quinazolin-4(3H)-one
2
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               Due to the broad spectrum of biological properties of derivatives of Quinazolinone 
their synthesis has been a focus of significant interest in recent years.
               The structure activity relationship studies of Quinazolinone ring system revealed in
various Literatures suggests position 2, 6 and 8 are very much important for structure activity
studies  and  position  3  should  be  attached  to  different  heterocyclic  rings  for  better
chemotherapeutic activity. 
                Of the various Quinazolines reported, the C-2 and N-3 disubstituted Quinazolines
exhibited  interesting  pharmacological  activities  like  analgesic,  anti  inflammatory,
anticonvulsant, antibacterial activities, etc 7
.
                 From the review of various Literatures, it was known that Quinazolin-4-ones have
emerged as an important class of nitrogenated Heterocycles that have attracted significant
synthetic  interest  because  of  their  therapeutic  and  Pharmacological  properties  such  as
antibacterial,  antifungal,  anthelmintic,  anti-inflammatory,  anticonvulsant,  CNS depressant,
hypoglycemic,  antiparkinsonian,  anticancer,  antiviral,  antihistaminic,  antihypertensive,
analgesic and many other activities.
3
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                                        REVIEW OF LITERATURE
1. Murugesan Dinakaran et al., synthesized 6-bromo-2, 3 disubstituted 4-(3H)- 
Quinazolinones and evaluated the antiviral & cytotoxic activity.8
            
                    
N
N
R2
R1
O
Br
N
N
CH2
OCH3
OCH3
OCH3
R2 =R1 = CH3(i)
R2 =
R1 = C6H5(ii)
N
N
Cl
NH2
C2H5
2. Veerachamy Alagarsamy et al., synthesized 3-cyclohexyl-2-substituted hydrazino-
3H-Quinazolin-4-ones as analgesic and anti-inflammatory agents.9
                                                 
N
N
O
NH
N
R1
R2
4
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CH2CH3
CH3
R2
R1
=
CH3
CH2CH3
CH2CH3
CH2CH2CH3
CH3
3. A.M.F Eissa et al., synthesized 2-propyl 4(3H)-Quinazolinone derivatives as 
antibacterial agents.10
                             
                                                
N
N
O
N
Ar-
                                
                                Ar = 3, 4 C6H3(OCH3)2
                                Ar = 4 C6H4 N(CH3)2
5
                                Ar = 3, 4 C6H302CH2
Chapter-I                                                                                                                              Review of Literature
4. Veerachamy Alagarsamy et al., synthesized novel 4-(3-ethyl phenyl)-1-substituted-
4H-[1,2,4] triazolo [4,3-a] quinazolin-5-ones as a new class of H1- antihistaminic 
agents.11
                                                  
N
N
O
N
N
R
C2H5
                           
                                  R= -SH, -SCH3, NHNH2, -H, 
                                        -CH3, -CH2CH3,
                                       -(CH2)2 CH3, -CH2Cl,
                                       
N N
,
5. Veerachamy  Alagarsamy et al., synthesized novel -2 phenyl 3-substituted 
Quinazolin-4(3H)ones as analgesic, anti-inflammatory & antibacterial agents.12
                                      
N
N
O
NH
C6H5
C R
S
6
                  
                                
CH3
N
CH3
R=
, C2H5
N
C2H5
, N
,
O
N
NH CH3
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6. Veerachamy  Alagarsamy et al., synthesized novel -2, 3-Disubstituted Quinazolin-
4(3H)ones as analgesic & anti-inflammatory agents.13
                                         
N
N
O
N
C6H5
R
                              
CH2CH3
CH3
R= CH CH CH CH
N
H
O
,
,
,
  
              
                      
7. Veerachamy  Alagarsamy et al., synthesized novel -2 methyl  thio 3-substituted 
Quinazolin-4(3H)ones as analgesic, anti-inflammatory & antibacterial agents.14
7
                               
N
N
O
NH
SCH3
C
S
R
              
R= NH CH3 , N
CH3
CH3
,
N
C2H5
C2H5 ,
N ON
,
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8. Veerachamy  Alagarsamy et al., synthesized 1,4-Disubstituted 1,2,4-triazolo[4,3-a] 
Quinazolin-5(4H)ones.15
                                  
N
N
O
N
N
R
               R= -H, -CH3, -C2H5, -(CH2)2CH3, -CH2Cl
9. Veerachamy  Alagarsamy et al., synthesized 3 –(4-methoxy phenyl) 2-substituted 
amino  Quinazolin-4(3H)ones as analgesic & anti-inflammatory agents.16
                                       
N
N
O
NH
N
R1
R2
OCH3
8
                        
CH2CH3
CH3
CH2CH3
CH2CH3
CH2CH2CH3
CH3
R2
R1
=
H
, ,
,
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10. Usha Ameta et al., synthesized 3-[(5-arylidene-4-oxo-1,3-thiazolidin-2-
yliden)amino]-2-phenyl quinazolin-4(3H) ones and their ethoxy phthalimide 
derivatives.17
                                          
N
N
O
N
S
N
O
CH
R
R1
                                
R= OCH3 , , N
CH3
CH3
OH
OCH3
, Cl
R1= N
O
O
O(H2C)2
9
11. Veerachamy  Alagarsamy et al., synthesized 1-substituted  4- (3-methyl phenyl) 
1,2,4-triazolo[4,3-a] Quinazolin-5(4H)ones.18
                            
N
N
O
N
N
R
CH3
                R= -H, -CH3, -C2H5, -(CH2)2CH3, -CH2Cl
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12. Veerachamy  Alagarsamy et al., synthesized novel -2 –butyl 3-substituted 
Quinazolin-4(3H)ones.19
                              
                            
N
N
O
NH
C4H9
C
S
R
                    
R= NH CH3 , N
CH3
CH3
,
N
C2H5
C2H5 ,
N ON
,
NHN
,
13. Vinod K.Tiwari et al., synthesized 3-heteroaryl-2-thioxo-2,3-dihydro quinazolin-4-
(1H)-one.20
10
                                       
N
N
O
S
X
NN
R2
R1
                      X= O,S                     R= H,Cl             
                      R1= H,CH3               R2= CH3,H 
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14. P.Mani Chandrika et al., Synthesized novel 2,4,6-tri substituted quinazoline 
derivatives as anti bacterial and cytotoxic agents.21
                                          
N
N
Cl
R
X
                     X= H                        R= C6H5, CH3, CF3, I, Br
15. M.B. Raju et al., Synthesized 3- [(N,N-Dialkyl amino)alkyl)-1,2,3,4-tetrohydro –
(1H)-thio quinazolin-4(3H)-ones and their oxo analogues as antihistaminic agents.22
11
                          
N
N
H
O
S
(CH2)n
R
R
N
N
H
O
O
(CH2)n
R
R
                          R= -CH3, -CH2CH3, C4H9             n= 2, 3
16. E.M. Jessy et al., Synthesized some novel Quinazolones.23
                               
N
N
O
CH CH R5
R
R1
R2
R3
R4
                            R= COOH, H                        R1= H, COOH             R2=H, Br
                            R3= Cl, H                              R4= H, Cl                     R5= NO2, OCH3, F, OH
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17. L. Cipak et al., Synthesized 2-phenoxy methyl 3-H Quinazolin-4-one as anticancer 
agents.24
                                
                              
NH
N
O
CH2 O
12
18. Maykel cruz-Monteagudo et al., Synthesized 3-(3-Methyl phenyl)-2-substituted 
amino-3H- Quinazolin-4-ones as analgesic, anti-inflammatory & ulcerogenic 
agents.25
                                 
N
N
O
NH
N R
CH3
                        
CH2CH3
CH3
CH2CH3
CH2CH3
CH2CH2CH3
CH3
=
H
, ,
,
R
,
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19. N.M.Raghavendra et al., Synthesized Novel substituted piperazinyl quinazolin-3-
(4H)-ones as antimicrobial agents.26
                                       
N
N
O
X
X
R
NH C
O
CH2 R1
13
                                  X= H, Br                       
                                  R= C6H5, CH3
                      R1= piperazinyl, 4-methyl piperazin-1-yl,
                              4-ethyl piperazin-1-yl, 
                              4-phenyl   piperazin-1-yl
20. Chang Xie et al., Synthesized imidazo [2, 1-b] quinazoline-2,5 (1H,3H)-diones.27
                                           
N
N
O
N
R1
R2
O
                      R1= Ph, 4-chloro phenyl, 
                              3-methyl phenyl         
                      R2= H, CH3, C6H5CH2
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21. Sachin S. Laddha et al., Synthesized 6,8 disubstituted 2-phenyl 3[substituted-
benzothiazol-2-yl]-4(3H)-quinazolinones.28
14
                                                 
N
N
O
C6H5
X
X S
N
R4 R5
R6
                             X= Br,            R4= H, OCH3, CH3, OC2H5        R5= H, OCH3, CH3, OC2H5    
                                                    R6= H, OCH3, NO2, OC2H5              
22. Veerachamy  Alagarsamy et al., synthesized 3 –(4-methyl phenyl) 2-substituted 
amino  Quinazolin-4(3H)ones as analgesic & anti-inflammatory agents.29
                                         
N
N
O
NH
N
R1
R2
CH3
                   
CH2CH3
CH3
CH2CH3
CH2CH3
CH2CH2CH3
CH3
R2
R1
=
H
, , ,
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15
23. Periyasamy Selvam et al., Synthesized novel 2-phenyl 3-Disubstituted quinazolin-
4(3H)-ones.30
                                           
N
N
O
R1
R2
R3
                                R1= H, Br                        R2= H, Br
                                
R3= SO2NH
O
N
CH3 ,
N
24. Veerachamy  Alagarsamy et al., synthesized 3 –(benzyl) 2-substituted amino  
Quinazolin-4(3H)ones as analgesic & anti-inflammatory agents.31
                               
N
N
O
NH
N
R1
R2
            
CH2CH3
CH3
CH2CH3
CH2CH3
CH2CH2CH3
CH3
R2
R1
=
H
, , ,
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16
25. N.M.Raghavendra, M.S.Niranjan et al., reported on the synthesis of substituted 2-
phenyl quinazolin-4-ones and studied their antitumor and antimicrobial activity.32
                                                    
N
N
O N CH
Br
26. Mohamed A Abdo et al., reported  on some reactions of 2-phenyl-4-(3H) 
quinazolinones.33
                                                        
N
N
O NH N
Br
CHR
                                   
R= COOEt ,
NH
N
HO
O
O
,
N
N
H
CH3
CH3
27. Anil.K.Sengupta, Tapas Bhattacharya reported on synthesis and antimicrobial 
activity of some substituted 2-phenyl -3-aryl quinazol-4-ones.34
                                         
N
N
O
R1
COOEt
OH
R
                                       I) R=R1=H,      II) R=H, R1=Br,           III) R=R1=Br
17
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28. S.Dev Singh et al., reported on synthesis and H1-antihistaminic evaluation of 3-
[(N,N-dialkyl amino) alkyl]-6-halo-2-phenyl-3,4-dihydro quinazolin-4(3H)-ones.35
                                        
N
N
O
X (CH2)n N
R
R
                                          X= Br, I    
                                          n= 2, 3       
                                          R= CH3, C2H5, C4H9
29. P.Selvam et al., reported on synthesis and cytostatic activity of some 3-[5-amino-
6(2,3 dichlorophenyl) – [1,2,4] triazin-3yl]- 6,8 dibromo-2-substituted -3H-
Quinazolin-4-ones. 36
                                  
                                           
N
N
O
R
R2
R1
N
N
N
NH2
Cl
Cl
                                             R= CH3, C2H5, C6H5               
                                             R1, R2= H, Br
18
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30. R.K. Kawadkar, B.J. Ghiya reported on synthesis of New Quinazolin-4-one 
compounds of Medicinal importance.37
                                                
N
N R
R1
O
                                  R= CH3, C6H5                            
                                  
C
NH
NH2R
1
=H,
,
NH C
S
NH
31. Pradeep Mishra, P. Paneer Selvam reported on the synthesis of 2- methyl 
Quinazolin-$(3H) ones and studied their antimicrobial activity.38
                                                   
N
N CH3
Ar-
O
X
X
                                                  X= H, Br     
                                                  Ar= o-C6H4COOH, o-C6H4OH, 
                                                          p- C6H4NO2, p-C6H4SO3H
19
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32. V. Malla Reddy, V. Murugan et al., reported on the synthesis of some 2-alkyl 3-
aryl-4 (3H) Quinazolinones as possible antitumor agents.39
                                                
N
N CH2
O
X
R
N
CH2CH2Cl
CH2CH2Cl
X1
 
                                                  R= 4-Cl, 4-OC2H5, 4-NO2                     
                                                  X= H, 6-Cl              
                                                  X1= 6-Br, 8-Cl
33. V. Murugan, et al.,reported on the synthesis of 2- substituted Quinazolin-4 (3H)-
ones as a new class of anticancer agents.40
                                         
N
N
O
Br
CONHNHC 6H5
Br
Ar-
                                  Ar= -C6H5, -CH=CH-C6H5, -m-C6H5NO2
20
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34. N.B.Patel and J.D. lilakar reported on the synthesis and antibacterial activity of 
new substituted 4(3H) Quinazolinones.41
                                           
N
N
O
CH2
NH
Cl
Cl
R
                             R=H, 2-NO2, 2-CH3, 2-OCH3, 2-Cl,
                                  3-NO2, 3-CH3, 3-OCH3, 3-Cl,
35. Ashok Kumar, V.K. Srivastava reported on the synthesis and anti-inflammatory 
activity of some New 2, 3 disubstituted-6-monosubstituted-Quinazolin-4(3H)-ones.42
                                     
N
N
O
X
N
O
NH C
O
CH CH
R
R1
                      
21
                            X= Br, H            
                            R= o-Cl, o-OCH3, m-Cl, H                                                                            
                            R1=m-OCH3, p-OH, p-N(CH3)2, p-OCH3
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36. Ashok Kumar, Mirdula Tyagi et al.,reported on the synthesis and hypotensive 
activity of New potential Quinazolinones.43
                         
N
N
O
Br
CH2 CH2 NH
NH CH2 CONH
R1
N
C
O
Cl
R
                           R= 4-OCH3, 3-OCH3, 4-OH, 4-N(CH3)2, H
                           R1= o-Cl, H, p-Cl,p-OCH3
37. P.C. Sarkar et al.,on the synthesis and biological evaluation of some New 2-aryl/ 
substituted aryl -6,8-substituted Quinazol-4(3H)-ones.44
                                   
N
N
O
X2
N
S R2
R3
R4
X1
R1
22
                   X1=X2=R2=R3=R4=H                 R1= C6H5-
                   X1=X2=R2=R3=R4=H                 R1= p-ClC6H4-
                   X1=X2=R2=R3=R4=H                 R1= m-ClC6H4-
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38. Bernard Pirotte et al.,reported on the synthesis and KATP channel activity of 2-alkyl 
amino-6-halogeno Quinazolin-4(3H)-ones.45
                                       
NH
N
O
X
N
R
H
(i) X= Cl, I            R=CH(CH3)2
(ii) X= Cl, I            R=CH(CH3)CH2CH3
(iii) X= Cl, I            R=CH(CH3)CH(CH3)2
(iv) X= Cl, I            R=CH2C6H11
39. PSN Reddy et al., reported on the synthesis of novel Bis Quinazolinyl-Beta 
lactams.46
                             
N
N
O
N
O
z N
O
N
N
CH3
O
CH3
23
Z=1, 4 C6H4, 4,4’- C6H4- C6H4,
4,4’- C6H3 (3-CH3)- C6H3(3’-CH3)
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40. H.M.F, Madkour reported on the reactivity of 4H-3, 1-benzoxazin-4-ones towards 
nitrogen and carbon nucleophilic reagents.47
                                                    
N
N
O
NR3
R1
R2
Br
                              R1= Isopropyl, Methyl                               
                              R2= Br
                              R3= Nitrogen nucleophiles – NH2OH, HCl,                       
                                    
COCH 3NH2 ,
NH2
NH2
, SO2NH2NH2
                                      Carbon electrophiles:  Benzaldehyde, 
                                                                          4-methoxy benzaldehyde, 
                                                                          4-chloro benzaldehyde
41. V.Alagarsamy et al., Synthesized 2 substituted (1,3,4)  Thiadiazolo Quinazolines.48
24
                                                    
N
N
O
N
S R
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42. V.Alagarsamy et al., Synthesized Novel-2-Methyl 3-Substituted Methylamino –
(3H)- Quinazolin-4-ones as Anti HIV, Antibacterial & Antifungal agents.49
                                           
N
N
NH
O
CH2 NH R
CH3
R= (CH3)2 , (C2H5)2 ,
N
H
,
O
N
H
,
N
H
N
H
        
43. Ahmad  R.  Khosropour,  Iraj  Mohammadpoor-Baltorka  and  Hamid
Ghorbankhani,    Bi(TFA)3–[nbp]FeCl4:  a  new,  efficient  and  reusable  promoter
system for the synthesis of 4(3H)-quinazolinone derivatives.50
25
COOH
NH2
+ RNH2
HC(OCH 3)3
Bi(TFA) 3
-[nbp]FeCl 4
N
N
O
R
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44. Tsuyoshi Nagase, Takashi Mizutani et al., Synthesis and Evaluation of Structurally
Constrained Quinazolinone Derivatives as Potent and Selective Histamine H3 
Receptor Inverse Agonists.51
N
N
CF3 O
O N
45. Joachim Rudolph,  William P. Esler et al., Synthesis a Quinazolinone Derivatives 
as Orally Available Ghrelin Receptor Antagonists for the Treatment of Diabetes and 
Obesity.52
26
NN
O
N R
1
Cl
R1
  Et. i Ph, =
O
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46. Hirohiko  Hasegawa, Masami  Muraoka  et  al.,  Discovery  of  a  Novel  Potent
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N
N
x
y
O
NH
O
N
N
R1
n
R2
                             X = H, H, H, H, H
                 Y= H, H, H, H, H
                 R1= H, H, H, H, H
                 R2=H, o-Cl, p-Cl, p-Me, 2,3-Me2
                      n= 0, 0, 0, 0, 0
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                                      OBJECTIVE OF PRESENT WORK
Quinazolin-4-(3H)-one is a versatile lead molecule for the design of potential
bioactive agents.30, 55
                                                            
NH
N
O
quinazolin-4(3H)-one
                 From the literature review, it was known that most of the Quinazolin-4-(3H)- ones
having substitution at C-2 and N-3 positions possess various interesting  pharmacological
activities.
     In the present work, Novel 2-butyl-3-amino (substituted)quinazolin-4(3H)-ones
 were synthesized and their analgesic and anticonvulsant activities were evaluated. 
The objective of the present work can be summarized as follows:
I) Synthesis:
To  synthesize  2-butyl-3-substituted  amino  quinazolin-4(3H)-one  derivatives  by  the
following steps
 First step is the cyclization of Anthranilic acid with Valeric anhydride to give 2-
butyl-4H-3, 1-benzoxazin-4-one.
                             
O
N
O
C4H9
2-butyl-4H-3,1-benzoxazin-4-one
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 Second  step  is  the  condensation  of  2-butyl-4H-3,1-benzoxazin-4-one  with
hydrazine hydrate to yield 3-amino-2n-butyl Quinazolin-4(3H)-one
                         
N
N
O
C4H9
NH2
3-amino-2-butylquinazolin-4(3H)-one
 Third step is the substitution of various amines to yield 3-substituted amino-2n-
butyl Quinazolin-4(3H)-one derivatives 56, 57
                                                  
N
N
C4H9
O
NH CH2 R
                                  3-substituted amino-2n-butyl Quinazolin-4(3H)-one
II) Characterization: 
                    Characterization of the synthesized compounds by the analytical technique like
thin  layer  chromatography, Infrared  spectral  analysis,  Nuclear
magneticresonance spectral analysis methods.
III) Pharmacological Screening:
 Screening of the synthesized compounds for Anticonvulsant activity against
        electrically induced seizures.
 Screening of the synthesized compounds for Analgesic activity by aceticacid 
 induced writhing method.
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                                        SCHEME OF REACTION
                        
NH2
O
OH
+
CH3 CH2 CH2 CH2 CO
CH3 CH2 CH2 CH2 CO
O
N
O
C4H9
Anthranilic Acid Valeric anhydride
Reflux for 3 hours
2-butyl-4H-3,1-benzoxazin-4-one
NH2 NH2 OH2.Ethanol
N
N
O
C4H9
NH2
3-amino-2-butylquinazolin-4(3H)-one
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N
N
O
C4H9
NH2
3-amino-2-butylquinazolin-4(3H)-one
HCHO
Ethanol
N
N
O
NH CH2 N
CH3
CH3
C4H9
N
N
O
NH CH2 N
C2H5
C2H5
C4H9
N
N
O
NH CH2 N
C6H5
C6H5
C4H9
N
N
O
NH CH2 NH
C4H9
N
N
O
NH CH2 NH
C4H9
Br
2-butyl-3-{[(dimethylamino)methyl]amino}quinazolin-4(3H)-one
2-butyl-3-{[(diethylamino)methyl]amino}quinazolin-4(3H)-one
2-butyl-3-{[(phenylamino)methyl]amino}quinazolin-4(3H)-one
3-({[(4-bromophenyl)amino]methyl}amino)-2-butylquinazolin-4(3H)-one
2 -butyl -3 -{[(diphenylamino)methyl]amino}quinazolin -4(3H) -one
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N
N
O
NH CH2 NH
C4H9
NO2
N
N
O
NH CH2 NH
C4H9
COOH
N
N
O
NH CH2 NH
C4H9
SO2NH2
N
N
O
NH CH2 N
C4H9
N
N
O
NH CH2 N
N
N
C4H9
N
N
O
C4H9
NH2
HCHO
Ethanol
3-amino-2-butylquinazolin-4(3H)-one
2-butyl-3-({[(4-nitrophenyl)amino]methyl}amino)quinazolin-4(3H)-one
4-({[(2-butyl-4-oxoquinazolin-3(4H)-yl)amino]methyl}amino)benzoic acid
2-butyl-3-[(1H-indol-1-ylmethyl)amino]quinazolin-4(3H)-one
3-[(1H-benzotriazol-1-ylmethyl)amino]-2-butylquinazolin-4(3H)-one
4 -({[(2 -butyl -4 -oxoquinazolin -3(4H) -yl)amino]methyl}amino)benzene sulphonamide
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                                                             SYNTHESIS
                                        EXPERIMENTAL WORK
SYNTHESIS
STEP I:
             SYNTHESIS OF 2(N-BUTYL) -3H-QUINAZOLIN-4-ONE19
CHEMICALS REQUIRED
          Anthranilic acid  
          Pentanoic anhydride
          
PROCEDURE
          A mixture of anthranilic acid (0.01 mol) and pentanoic anhydride (0.05 mol) was
refluxed under anhydrous conditions for 3 hours.
         Excess liquid was distilled off under reduced pressure and the reaction mixture was
cooled to room temperature. 
32
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SYNTHESIS OF 2-BUTYL-4H-3,1-BENZOXAZIN-4-ONE:
NH2
O
OH
+
CH3 CH2 CH2 CH2 CO
CH3 CH2 CH2 CH2 CO
O
O
N
O
C4H9
STEP - I:
Anthranilic Acid Valeric anhydride
Reflux for 3 hours
2-butyl-4H-3,1-benzoxazin-4-one
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SYNTHESIS
STEP II:
               SYNTHESIS OF 3-AMINO-2-(N-BUTYL)-3H-QUINAZOLINE-4-ONE19
CHEMICALS REQUIRED
       Pyridine
       Hydrazine Hydrate
       Conc. Hydrochloric Acid
PROCEDURE
          The solid obtained was dissolved in pyridine (50ml) and hydrazine hydrate(0.02 mol) 
was added to it and then refluxed for 4 hours. Cool to room temperature and pour it in to a 
mixture of ice (50g) and conc. Hydrochloric acid (50 ml).
      The reaction mixture was kept overnight. The solid separated was filtered, Washed well 
with water, dried and recrystallised from ethanol.
   
  
34
Chapter-III                                                                                                                                               Synthesis
               SYNTHESIS OF 3-AMINO-2-BUTYLQUINAZOLIN-4(3H)-ONE:
               
O
N
O
C4H9
+ NH2 NH2 . OH2
N
N
O
C4H9
NH2
3-amino-2-butylquinazolin-4(3H)-one
Pyridine
STEP - II:
2(n - butyl)-3H - quinazolin 4(one) Hydrazine Hydrate
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SYNTHESIS 56, 57, 58
STEPIII
         SYNTHESIS OF  3-SUBSTITUTED-2-(N-BUTYL)-3H-QUINAZOLINE-4-ONE49
CHEMICALS REQUIRED
       Amine 
       Formaldehyde(37-41%)
       Dimethyl formamide
       Ethanol  
PROCEDURE
        A mixture of formalin (37-41% ; 1ml) and  amine (0.005mol) drop by drop with stirring
to a slurry of 3-amino-2-butyl-3(H)quinazolin-4-one( 0.005 mol) in dimethylformamide (15
ml). The reaction mixture was heated on a water bath for about 25min .  After cooling , it was
poured  in  to  ice  water.  The  solid  obtained  was  filtered  washed  with  water,  dried  and
recrystallized from ethanol .
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        SYNTHESIS OF 2-BUTYL-3-{[(AMINO SUBSTITUTED)METHYL]AMINO}
        QUINAZOLIN-4(3H)-ONE:
N
N
C4H9
O
NH2 + HCHO +  R'H
Mannich Reaction
N
N
C4H9
O
NH CH2 R
Formaldehyde
Step III :
Amine Containing Compounds
3-amino-2-butylquinazolin-4(3H)-one
Reflux for 4 hrs
Ethanol
                 2-butyl-3-{[(amino substituted) methyl]amino}quinazolin-4(3H)-one
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SYNTHESIS
stepIII
         Synthesis of  2-(n-butyl)-3-{[(dimethylamino)methyl]amino}quinazoline -4(3H)-one49
CHEMICALS REQUIRED
       Dimethyl Amine 
       Formaldehyde(37-41%)
       Dimethyl formamide
       Ethanol  
PROCEDURE
         A mixture of formalin (37-41% ; 1ml) and dimethyl amine (0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one  (0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min.  After cooling, it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol.
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           SYNTHESIS OF 2-BUTYL-3-{[(DIMETHYLAMINO)METHYL]AMINO}
           QUINAZOLINE-4(3H)-ONE:
            
Substitution with Dimethylamine :
N
N
O
NH2
C4H9
+ HCHO + NH
CH3
CH3
Formaldehyde Dimethyl amine3-amino-2-butylquinazolin-4(3H)-one
N
N
O
NH
C4H9
CH2 N
CH3
CH3
2-butyl-3-{[(dimethylamino)methyl]amino}quinazolin-4(3H)-one
Mannich Reaction
STEP III:
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII
             Synthesis of  2-(n-butyl)-3-{[(diethylamino)methyl]amino}quinazoline  -4(3H)-one49
CHEMICALS REQUIRED
       Diethyl Amine 
       Formaldehyde(37-41%)
       Dimethyl formamide
       Ethanol  
 
PROCEDURE
             A mixture of formalin (37-41%; 1ml) and diethyl amine (0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)  quinazolin-4-one  (0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min.  After cooling, it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol.
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           SYNTHESIS OF 2-BUTYL-3-{[(DIETHYLAMINO)METHYL]AMINO}
           QUINAZOLIN-4(3H)-ONE:
            
N
N
O
NH2
C4H9
+ HCHO + NH
C2H5
C2H5
Formaldehyde Diethyl amine
N
N
O
NH
C4H9
CH2 N
C2H5
C2H5
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Diethylamine :
STEP III:
2-butyl-3-{[(diethylamino)methyl]amino}quinazolin-4(3H)-one
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII
          Synthesis of  2-(n-butyl)-3-{[(diphenylamino)methyl]amino}quinazoline -4(3H)-one49
CHEMICALS REQUIRED
       Diphenyl Amine 
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol  
      
PROCEDURE
                 A mixture of formalin (37-41%; 1ml) and  diphenylamine (0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one(  0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min .  After cooling , it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol .
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    SYNTHESIS OF 2-BUTYL-3-{[(DIPHENYLAMINO)METHY]}
    QUINAZOLIN-4(3H)-ONE:
    
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Diphenylamine :
Diphenyl amine
N
N
O
NH CH2 N
C4H9
NH
STEP III:
Reflux for 4 hrs
Ethanol
                                2-butyl-3-{[(diphenylamino)methyl]amino}quinazolin-4(3H)-one
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SYNTHESIS
stepIII
               Synthesis of  2-(n-butyl)-3-{[(phenylamino)methyl]amino}quinazoline -4(3H)-one49
CHEMICALS REQUIRED
      Aniline 
      Formaldehyde (37-41%)
      Dimethyl formamide
      Ethanol  
       
PROCEDURE
                  A mixture of formalin (37-41%; 1ml) and aniline (0.005mol) drop by drop with
stirring  to  a  slurry  of  3-amino-2-butyl-3(H)-quinazolin-4-one  (0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min.  After cooling, it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol.
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        SYNTHESIS OF 2-BUTYL-3-{[(PHENYLAMINO)METHYL]AMINO}
        QUINAZOLIN-4(3H)-ONE:   
        
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
N
N
O
NH
C4H9
CH2 NH
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Aniline :
STEP III:
NH2
2-butyl-3-{[(phenylamino)methyl]amino}quinazolin-4(3H)-one
aniline
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII
         Synthesis of  3-({[(4-bromophenyl)amino]methyl}amino) -2-butylquinazolin-
         -4(3H)one49
      
CHEMICALS REQUIRED
       4- bromo Aniline 
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol   
PROCEDURE
               A mixture of formalin (37-41% ; 1ml) and 4- bromoaniline (0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one(  0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min .  After cooling , it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol .
.
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           SYNTHESIS OF 3-({[(4-BROMOPHENYL)AMINO]METHYL}AMINO)
           -2-BUTYLQUINAZOLIN-4(3H)-ONE:
            
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
N
N
O
NH
C4H9
CH2 NH Br
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with 4 - Bromo Aniline :
4-bromoaniline
STEP III:
Br NH2
3-({[(4-bromophenyl)amino]methyl}amino)-2-butylquinazolin-4(3H)-one
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII
             Synthesis of  2-butyl 3-({[(4-nitrophenyl)amino]methyl}amino) quinazolin
            -4(3H)-one49
      
CHEMICALS REQUIRED
       4- Nitro Aniline 
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol  
       
PROCEDURE
              A mixture of formalin (37-41% ; 1ml) and 4-nitro aniline (0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one(  0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min .  After cooling , it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol .
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           SYNTHESIS OF 2-BUTYL-3-({[(4-NITROPHENYL)AMINO]METHYL}
           AMINO)QUINAZOLIN-4(3H)-ONE:
            
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
N
N
O
NH
C4H9
CH2 NH NO2
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with 4 - Nitro Aniline :
STEP III:
NH2O2N
4-nitroaniline
2-butyl-3-({[(4-nitrophenyl)amino]methyl}amino)quinazolin-4(3H)-one
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII                          
Synthesis of 4-({[(2-butyl-4-oxoquinazolin-3(4H) -yl) amino] methyl} amino)
benzoic acid49
      
CHEMICALS REQUIRED
       Para amino benzoic acid 
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol  
PROCEDURE
            A mixture of formalin (37-41% ; 1ml) and  para amino benzoic acid (0.005mol) drop
by drop with stirring to a slurry of 3-amino-2-butyl-3(H)quinazolin-4-one(  0.005 mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min.  After cooling, it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol.
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            SYNTHESIS OF 4-({[(2-BUTYL-4-OXOQUINAZOLIN-3(4H)-YL)AMINO]
           METHYL}AMINO)BENZOIC ACID:
             
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
N
N
O
NH
C4H9
CH2 NH COOH
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Para Amino BenzoicAcid :
STEP III:
NH2HOOC
Para Amino BenzoicAcid
4-({[(2-butyl-4-oxoquinazolin-3(4H)-yl)amino]methyl}amino)benzoic acid
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII
             Synthesis of 4-({[(2-butyl-4-oxoquinazolin-3(4H)-  yl) amino]methyl} amino)
             benzene sulphonamide49
      
CHEMICALS REQUIRED
       Sulphanilamide
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol  
PROCEDURE
            A mixture of formalin (37-41% ; 1ml) and  sulphanilamide(0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one(  0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min .  After cooling , it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol .
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SYNTHESIS OF 4-({[(2-BUTYL-4-OXOQUINAZOLIN-3(4H)-  YL) AMINO]
METHYL} AMINO)BENZENE SULPHONAMIDE:
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
N
N
O
NH
C4H9
CH2 NH SO2NH2
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Sulphanilamide :
STEP III:
NH2H2NO2S
4-aminobenzenesulfonamide
Reflux for 4 hrs
Ethanol
                   4-({[(2-butyl-4-oxoquinazolin-3(4H)-  yl) amino]methyl} amino)
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                   benzene sulphonamide
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SYNTHESIS
stepIII
                 Synthesis of  2-butyl-3-[(1H-indol-1-yl methyl)amino] quinazolin-4(3H) –one49  
CHEMICALS REQUIRED
       Indole
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol  
PROCEDURE
                  A mixture of formalin (37-41% ; 1ml) and  indole (0.005mol) drop by drop with
stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one(  0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min.  After cooling, it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol.
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             SYNTHESIS OF 2-BUTYL-3-[(1H-INDOLE-1YLMETHYL)AMINO]
             QUINAZOLIN-4(3H)-ONE:
55
               
N
N
O
NH CH2 N
C4H9
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Indole :
STEP III:
N
H
Indole
2-butyl-3-[(1H-indol-1-ylmethyl)amino]quinazolin-4(3H)-one
Reflux for 4 hrs
Ethanol
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SYNTHESIS
stepIII
          Synthesis of  3-[(1H-benztriazole-1yl methyl)amino]-2-butyl quinazolin-4(3H)-one49  
56
CHEMICALS REQUIRED
       Benztriazole
       Formaldehyde (37-41%)
       Dimethyl formamide
       Ethanol  
PROCEDURE
                    A mixture of formalin (37-41%; 1ml) and  benztriazole (0.005mol) drop by drop
with  stirring  to  a  slurry  of  3-amino-2-butyl-3(H)quinazolin-4-one(  0.005  mol)  in
dimethylformamide (15 ml).  The reaction mixture was heated  on a water  bath for  about
25min.  After cooling, it was poured in to ice water. The solid obtained was filtered washed
with water, dried and recrystallized from ethanol.
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SYNTHESIS OF 3-[(1H-BENZOTRIAZOL-1YLMETHYL)AMINO]-2-BUTYL
QUINAZOLIN-4(3H)-ONE:
57
 N
N
O
NH CH2 N
N
N
C4H9
N
N
O
NH2
C4H9
+ HCHO +
Formaldehyde
Mannich Reaction
3-amino-2-butylquinazolin-4(3H)-one
Substitution with Benztriazole :
STEP III:
N
H
N
N
Benztriazole
3-[(1H-benzotriazol-1-ylmethyl)amino]-2-butylquinazolin-4(3H)-one
Reflux for 4 hrs
Ethanol
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PHYSICAL DATA OF THE TITLED COMPOUND
                                                                                                         Table No:1
Compound
    Code
Chemical Name Molecular
Formula
Molecular
Weight(grams)
Percentage
Yield
      
Appearance
A1 2-butyl-3-{[(dimethylamino)methyl]  amino}
quinazolin-4(3H)-one
C15H22N4O 274.361 91.05% Solid
A2 2-butyl-3-{[(diethylamino)methyl]amino}
quinazolin-4(3H)-one
C17H26N4O 302.414 86.20% Solid
A3 2-butyl-3-{[(diphenylamino)methyl]amino}
quinazolin-4(3H)-one
C21H18N4O 342.394 88.83% Solid
A4 2-butyl-3-{[(phenylamino)methyl]amino}
quinazolin-4(3H)-one
C19H22N4O 322.404 84.23% Solid
A5 3-({[(4-bromophenyl)amino]methyl}amino)-2-
butylquinazolin-4(3H)-one
C19H21BrN4O 401.300 81.21% Solid
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Compound
    Code
Chemical Name Molecular
Formula
Molecular
Weight(grams)
Percentage
Yield
      
Appearance
A6 2-butyl-3-({[(4-nitrophenyl)amino]methyl} 
amino)quinazolin-4(3H)-one
C19H21N5O3 367.402 85.74% Solid 
A7 4-({[(2-butyl-4-oxoquinazolin-3(4H)-
yl)amino]methyl}amino)benzoic acid
C20H22N4O3 366.414 83.01% Solid 
A8 4-({[(2-butyl-4-oxoquinazolin-3(4H)-
yl)amino]methyl}amino)benzene 
Sulphonamide
C19H23N5O3S 401.483 75.75% Solid 
A9 2-butyl-3-[(1H-indol-1-
ylmethyl)amino]quinazolin-4(3H)-one
C21H22N4O 346.425 90.93% Solid 
A10 3-[(1H-benzotriazol-1-ylmethyl)amino]-2-
butylquinazolin-4(3H)-one
C19H20N6O 348.402 93.55% Solid 
Chapter-IV                                                                                                                                        Melting Point
                              MELTING POINT ANALYSIS
            Melting point was found in an open end capillary tube method by electrically 
heating melting point apparatus.
                The melting point of synthesized compounds is given in the Table No : 2
                                                                Table No: 2 
S.NO COMPOUND MELTING POINT 0C
    1. A1 206-209
2. A2 148-152
3. A3 226-230
4. A4 241-243
5. A5 272-275
6. A6 255-258
7. A7 236-239
8. A8 278-282
9. A9 222-227
10. A10 229-234
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THIN LAYER CHROMATOGRAPHY ANALYSIS
                 Thin layer chromatography analysis was carried out by using Silica gel G (0.5mm 
thickness) coated over glass plate (12x20cm) as stationary phase, Methanol: Chloroform: 
Water (8:1:1) as mobile phase, the spots were visualized by iodine vapours.
                  The Rf value of the synthesized compounds are given in the Table No: 3
                                                                  Table No: 3
S.No COMPOUND Rf  VALUE
1. A1 0.9459
2. A2 0.8714
3. A3 0.8472
4. A4 0.8873
5. A5 0.9054
6. A6 0.8243
7. A7 0.8667
8. A8 0.9577
9. A9 0.9305
10. A10 0.8933
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ANTI CONVULSANT ACTIVITY OF QUINAZOLINONE DERIVATIVES
 
                                          ELECTRO CONVULSOMETER
Chapter-VI                                                                                  Pharmacological Evaluation-Anti Convulsant
ANTI CONVULSANT ACTIVITY OF QUINAZOLINONE DERIVATIVES
FLEXION PHASE
EXTENSOR PHASE
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ANTI CONVULSANT ACTIVITY OF QUINAZOLINONE DERIVATIVES
CLONUS PHASE
STUPOR PHASE
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ANALGESIC ACTIVITY OF QUINAZOLINONE DERIVATIVES
WRITHING EFFECT
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INFRA RED SPECTRAL ANALYSIS 59-65
   The structure of the synthesized compounds was elucidated by PERKIN-ELMER FT-IR
spectrophotometry using potassium bromide disc.  The infra red values  were measured as
wave number in cm-1 and the results are shown below. 
  A-1 
                  2- butyl-3-{[(dimethylamino)methyl]amino}quinazolin-4(3H)-one
                                            
N
N
O
NH
C4H9
CH2 N
CH3
CH3
IR Values:
                3484.74 cm-1  - N-H Stretch (amine in side chain)
                3025.34 cm-1  -  C-H Stretch (in aromatic amine)
                2925.26 cm-1  -  C-H Stretch (in CH2 methylene bridge )
                2869.56 cm-1  -  C-H Stretch 
                1665.23 cm-1  -  C=O Stretch
                1510.95 cm-1  -  C=N Stretch
                1450.22 cm-1  -  C-H Bending
                1035.59 cm-1  -  C-C Stretch (in aliphatic ring)
                1079.31 cm-1  -  C-N Stretch
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A-2
                   2- butyl -3- {[(diethylamino)methyl]amino}quinazolin-4(3H)-one
                                         
N
N
O
NH
C4H9
CH2 N
C2H5
C2H5
IR Values:
                 3450.17cm-1  -  N-H Stretch (in side chain )
                 3080.33 cm-1  -  C-H Stretch (C-H Stretching in Aromatic ring)
                 2928.65cm-1  -  C-H Stretch
                 2885.93 cm-1 -  C-H Stretch (C-H Stretching in CH3)
                 1641.13 cm-1  -  C=O Stretch
                 1590.32 cm-1  -  C=N Stretch
      1111.76 cm-1  -  C-C Stretch
     1059.22 cm-1  -  C-N Stretch
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A-3 
         2-butyl-3-{[(diphenylamino)methyl]amino}quinazolin-4(3H)-one    
     
                                         
N
N
O
NH CH2 N
C4H9
IR Values:
     3339.17cm-1  -  N-H Stretch (in side chain )
                 3050.67 cm-1  -  C-H Stretch (C-H Stretching in Aromatic ring)
                 2932.47cm-1  -  C-H Stretch
                 2888.76 cm-1 -  C-H Stretch (C-H Stretching in CH3)
                 1663.66 cm-1  -  C=O Stretch
                 1592.94 cm-1  -  C=N Stretch
      1110.63 cm-1  -  C-C Stretch
     1050.53 cm-1  -  C-N Stretch
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A-4
 
                       2-butyl-3-{[(phenyl amino)methyl]amino}quinazolin-4(3H)-one
                                          
N
N
O
NH
C4H9
CH2 NH
IR Values 
               3460.34 cm-1   -   N-H Stretch (in side chain )
               3055.33 cm-1   -   C-H Stretch (C-H Stretching in Aromatic ring)
               2933.39 cm-1   -   C-H Stretch (CH2)
               2895.26 cm-1   -   C-H Stretch (C-H Stretching in CH3)
               1641.73 cm-1   -   C=O Stretch
               1596.12 cm-1   -   C=N Stretch
               1286.22 cm-1   -   C-C Stretch
   1120.11 cm-1   -   C-N Stretch
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A-5
                 3-({[(4-bromophenyl)amino]methyl}amino)-2-butylquinazolin-4(3H)-one
                                       
N
N
O
NH
C4H9
CH2 NH Br
             
IR Values:
     3429.33cm-1  -  N-H Stretch (in side chain )
                 3020.12 cm-1  -  C-H Stretch (C-H Stretching in Aromatic ring)
                 1495.67 cm-1  -   C=C Stretch (in Aromatic ring)
                 2869.86cm-1  -  C-H Stretch
                 2930.96 cm-1  -  C-H Stretch (C-H Stretching in CH2)
                 1655.74 cm-1  -  C=O Stretch
                 1594.62 cm-1  -  C=N Stretch
      1249.26 cm-1  -  C-C Stretch
66
     1070.42 cm-1  -  C-N Stretch (in side chain)
                 600.26 cm-1    -  C-Br Stretch
Chapter-V                                                                                                         Infra Red Spectroscopic Analysis
A-6
         
                           2-butyl-3-({[4-nitrophenyl]methyl}amino)quinazolin-4(3H)-one
                                   
N
N
O
NH
C4H9
CH2 NH NO2
 IR Values:
     3447.13cm-1 -  N-H Stretch (in side chain )
                 3080.33 cm-1 -  C-H Stretch (C-H Stretching in Aromatic ring)
                 2885.93cm-1  -  C-H Stretch
                 2930.96 cm-1  -  C-H Stretch (C-H Stretching in CH2)
                 1639.21 cm-1  -  C=O Stretch
                 1598.32 cm-1  -  C=N Stretch
      1111.76 cm-1  -  C-C Stretch
     1059.22 cm-1  -  C-N Stretch (in side chain)
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                 1535.67 cm- 1   - N-O Stretch
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A-7
                   4-({[(2-butyl-4-oxoquinazolin-3(4H)-yl)amino]methyl}amino)benzoic acid
                                      
N
N
O
NH
C4H9
CH2 NH COOH
   
IR Values:
     3340.11cm-1    -  N-H Stretch (in side chain )
                 3060.65 cm-1   -  C-H Stretch (C-H Stretching in Aromatic ring)
                 2889.34cm-1    -  C-H Stretch
                 2932.31 cm-1   -  C-H Stretch (C-H Stretching in CH2)
                 1634.38 cm-1   -  C=O Stretch
                 1570.23 cm-1   - C=N Stretch
      1116.58cm-1    -  C-C Stretch
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     1044.45 cm-1   - C-N Stretch (in side chain)
                 2690.97 cm-1   -   COOH Stretch
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A-8
         4-({[(4-oxoquinazolin-3-(4H)-yl) amino]methyl}amino)benzene sulphonamide
                                
N
N
O
NH
C4H9
CH2 NH SO2NH2
IR Values:
                3305.69 cm-1    -   N-H Stretch (in SO2NH2)
                2860.43 cm-1    -   C-H Stretch in CH3
                2924.12 cm-1    -   C-H Stretch (C-H Stretching in CH2)
                1660.23 cm-1    -   C=O Stretch
                1580.11 cm-1    -  C=N Stretch
69
     1103.34 cm-1    -   C-C Stretch
    1050.41 cm-1    -  C-N Stretch (in side chain)
                901.11   cm-1    -  S-N Stretch
                1370.56 cm-1    -  SO2 Stretch
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A-9
                2-butyl-3-[(1H-Indol-1-yl methyl)amino]quinazolin-4(3H)-one
                                        
N
N
O
NH CH2 N
C4H9
IR Values:
     3500.12cm-1    -  N-H Stretch (sharp)
                 3065.53cm-1    -  C-H Stretch (C-H Stretching in Aromatic ring)
                 2857.63cm-1    -  C-H Stretch
                 2930.06 cm-1   -  C-H Stretch (C-H Stretching in CH2)
                 1639.21 cm-1   -  C=O Stretch
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                 1563.63 cm-1   - C=N Stretch
      1124.33cm-1    -  C-C Stretch
     1060.19 cm-1   - C-N Stretch (in side chain)
                 2690.97 cm-1   -   COOH Stretch
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A-10
                  3-[(1H-benzotriazol-1-ylmethyl)amino]-2-butylquinazolin-4(3H)-one
    
                                         
N
N
O
NH CH2 N
N
N
C4H9
IR Values:
     3491.17cm-1   -  N-H Stretch (sharp)
                 3050.41cm-1   -  C-H Stretch (C-H Stretching in Aromatic ring)
                 2865.78cm-1   -  C-H Stretch
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                 2931.12 cm-1  -  C-H Stretch (C-H Stretching in CH2)
                 1654.38 cm-1  -  C=O Stretch
                 1598.26 cm-1  - C=N Stretch
      1110.82cm-1   -  C-C Stretch
     1069.91 cm-1  - C-N Stretch (in side chain)
                 3300.22 cm-1   - N-N Stretch
Chapter-V                                                                    Nuclear Magnetic Resonance Spectral Analysis
NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS 60, 63, 64
          The structures of the synthesized compounds were elucidated by BRUCKER 300
MHz     FT- NMR using TMS (Tetramethyl Silane) as internal standard. The Proton Magnetic
Resonance Spectroscopic values are measured in δ  ppm in CDCl3.
Sample A1
N
N
O
NH
C4H9
CH2 N
CH3
CH3
2-butyl-3-{[(dimethyl amino) methyl] amino}quinazolin-4(3H)-one
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                              1.2782              -               t,    2H,    C4H9
                                     2.2564              -              s,     6H,    N(CH3)2  
                                     7.5602              -              t,     1H,   C6-H
                                     7.3385              -              t,     1H,    C7-H                of Quinazolinone
                     8.0370              -             d,    1H,   C5-H                 moiety.
             8.0523              -             d,    1H,   C8-H
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Sample A2
N
N
O
NH
C4H9
CH2 N
C2H5
C2H5
                         2-butyl-3-{[(diethylamino)methyl]amino}quinazolin-4(3H)-one
                              1.2446               -              s,    10H,    N (C2H5)2
                                     2.3772              -              t,     2H,    C4H9  
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                                     7.600                -              t,     1H,   C6-H
                                     7.1245              -              t,     1H,    C7-H                of Quinazolinone
                     8.7050              -             d,    1H,   C5-H                 moiety.
             8.1333              -             d,    1H,   C8-H
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Sample A6
N
N
O
NH
C4H9
CH2 NH NO2
   2-butyl-3-({[(4-nitrophenyl)amino]methyl}amino)quinazolin-4(3H)-one
                               2.4169             -              t,     2H,    C4H9  
                                     7.8000-8.0150 -              m,    4H,    Ar-H  
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                                     7.1444              -             d,     1H,   C5-H
                                     7.5112              -              t,     1H,   C6-H                of Quinazolinone
                     8.0156              -             t,    1H,    C7-H                 moiety.
             8.9709              -             d,    1H,   C8-H
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Sample A8
N
N
O
NH
C4H9
CH2 NH SO2NH2
    
4 -({[(2 -butyl -4 -oxoquinazolin -3(4H) -yl)amino]methyl}amino)benzene sulphonamide
                               3.042               -              t,     2H,    C4H9  
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                                     7.398-7.791     -              m,    4H,    Ar-H  
                                     7.830                -              t,     1H,   C7-H
                                     8.313                -              t,     1H,   C6-H                of Quinazolinone
                     8.378                -             d,    1H,   C8-H                 moiety.
             8.7000              -             d,    1H,   C5-H
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Sample A9
N
N
O
NH CH2 N
C4H9
2-butyl-3-[(1H-indol-1-ylmethyl)amino]quinazolin-4(3H)-one
76
                               1.2000             -              t,     2H,    C4H9  
                                     7.5-7.6             -              m,    4H,    Ar-H  
                                     6.969               -              t,     1H,   C7-H
                                     7.367               -              t,     1H,   C6-H                of Quinazolinone
                     8.224               -             d,    1H,   C5-H                 moiety.
             8.250               -             d,    1H,   C8-H
77
Chapter-VI                                                                                  Pharmacological Evaluation-Anti Convulsant
ANTI CONVULSANT ACTIVITY 66-70
INTRODUCTION
Anti convulsant drugs are intended for the treatment of convulsive disorders in man.
Convulsions  may  arise  due  to  many  reasons  most  of  the  animal  techniques  used  for
evaluating anti – epileptic drugs.
The general principle is to produce seizures by electrical stimulation as by systemic
administration  of  convulsant  chemical  agent.  Eg:  pentylene  tetrazole  or  production  of  a
chronic, focal epileptogenic lesion.
By electrical stimulation of the brain a variety of seizers can be produced.
The principle being,
a) Supra maximal electrical shock
b) Psychomotor electrical shock
c) Minimal electrical shock
SUPRA MAXIMAL ELECTRICAL METHOD 
The electro shock assay in rat is used primarily as an indication for compounds which
are effective in grandmal epilepsy.
Male albino wistar rats are stimulated through are stimulated through pinna electrodes
(150 mA – alternating current, 0.2 sec – stimulus duration)
The resultant  seizure in normal rats shows a tonic phase of limb flexion around 2
seconds, followed by full tonic extension phase around 10 -13 seconds and a few clonic jerks
there after the number of post – tonic as physical death are noted.
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REQUIREMENTS:
Animal: Male albino wistar rats (200 – 250 g)
Drugs: standard (Phenytoin sodium (25 mg / kg))
Test: Synthetic drugs (5 mg / kg)
Instrument: Electro convulsiometer model, Ki – 9531
PROCEDURE:
1. Healthy albino wistar rats weighing from 200 – 250 g were selected. They were kept
in separate cages, fed with balanced diet, water and libitum
2. Then the animals were divided into 12 groups each groups containing four animals.
3. The first groups of animals were served as control, which received 0.5 ml DMSO.
4. Second group served as standard which received phenytoin sodium (25 mg/kg)
5. Third group treated with C2 compound (5 mg/kg)
6. Fourth group treated with C5 compound (5 mg/kg)
7. Fifth group treated with C6 compound (5 mg/kg)
8. Sixth group treated with C7 compound (5 mg/kg)
9. Seventh group treated with C8 compound (5 mg/kg)
10. Eighth group treated with C9 compound (5 mg/kg)
11. Ninth group treated with C1 compound (5 mg/kg)
12. Tenth group treated with C3 compound (5 mg/kg)
13. Eleventh group treated with C4 compound (5 mg/kg)
14. Twelfth group treated with C10 compound (5 mg/kg)
All  the  test  compounds  were  dissolved  in  solvent  like  DMSO  and  administered
through intra-peritoneal route.
The evaluation was started 30 mins after  administration of  test  compounds. Pinna
electrodes with the intensity of 150 mA current were used to deliver the stimuli.
Inhibition of seizure relative to the control was calculated and the data shown on the
table.
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ANTI CONVULSANT ACTIVITY OF VARIOUS SYNTHESIZED DRUGS BY SUPRA
MAXIMAL ELECTRICAL SHOCK METHOD
Table No: 4
Treatment Body Wt. Drug Dose Duration of
extension
phase in
seconds
% inhibition
of extension
phase
Group I 180 – 200 gm Normal saline 10 ml / kg 13.52 ± 0.12 ------
Group II 180 – 200 gm Phenytoin sodium 25 mg / kg 2.5 ± 0.20 81.50 %
Group III 180 – 200 gm A1 5 mg / kg 6.25 ±. 0.32 53.77 %
Group IV 180 – 200 gm A2 5mg/ kg 4.12 ± 0.31 69.52 %*a
Group V 180 – 200 gm A3 5 mg / kg 6.85 ±. 0.28 49.33 %
Group VI 180 – 200 gm A4 5 mg / kg 7.02 ±. 0.33 48.08 %
Group VII 180 – 200 gm A5 5 mg/ kg 4.20 ± .0.45 68.93 %*a
Group VIII 180 – 200 gm A6 5 mg / kg 4.35 ± 0.55 67.82 %*a
Group IX 180 – 200 gm A7 5 mg / kg 4.22 ± 0.40 68.78 %*a
Group X 180 – 200 gm A8 5 mg / kg 4.02 ±. 0.35 70.26 %*a
Group XI 180 – 200 gm A9 5 mg / kg 3.99 ±. 0.28 70.48 %*a
Group XII 180 – 200 gm A10 5 mg / kg 6.55 ±. 0.28 51.55 %
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• values are expressed as Mean ± SEM
• values  are  find  out  by using  One  way ANOVA followed  by Newman  Keul’s
multiple range test.
*a *a Values are significantly different from normal control at P<0.01.
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ANALGESIC ACTIVITY 69-72
EVALUATION OF ANALGESIC ACTIVITY
The analgesic activities of various synthesized compounds were screened by using
acetic acid induced writhing test in mice. Mice of either sex weighing between 20 –25 gm
were taken in12 groups of each 4 animals.
Diclofenac sodium 10mg/kg was used as a standard drug for comparison of analgesic
activity.  Writhing  was  induced  by  administration  0.2ml  of  1%v/v  of  aceticacid  through
intraperitoneally.  Record  the  number  of  abdominal  contractions,trunk  twist  response  and
extension of hind limbs as well as the number of animals showing such response during a
period of 25 min.
Administer  all  synthesized  compound  through  I.P.Half  an  hour  later  adminiser
aceticacid solution at  1ml/100gm B.W. Note and calculate onset  and severity of writhing
response. Note the inhibition of pain response by synthesized drugs.
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EFFECT OF ANALGESIC ACTIVITIES OF SYNTHESIZED COMPOUNDS
AGAINST ACETIC ACID INDUCED WRITHING TESTS IN MICE.
Table No: 5
GROUP COMPD DOSE NO FO WRITHES IN
25MIN(Mean ± SEM)
%INHIBITION
G1(Normal
control)
Normal saline 10 ml / kg 27.90±.0.40 -----
G2 (STD) Diclofenac
sodium
10 mg / kg 7.45±0.62. 73.29%
G3(Treatment
control)
A1 5 mg / kg 8.95±0.72 67.92%*a
G4 A2 5mg/ kg 8.58±0.45 69.24%*a
G5 A3 5 mg / kg 13.54±1.65 51.46%
G6 A4 5 mg / kg 13.5±1.25 51.61%
G7 A5 5 mg/ kg 8.22±0.52 70.53%*a
G8 A6 5 mg / kg 12.70 ±1.33 54.48%
G9 A7 5 mg / kg 12.85±1.22 53.94%
G10 A8 5 mg / kg 8.50±0.74 69.53%*a
G11 A9 5 mg / kg 8.62±0.45 69.10%*a
G12 A10 5 mg / kg 8.83±0.76 68.35%*a
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• values are expressed as Mean ± SEM
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• values  are  find  out  by using  One  way ANOVA followed  by Newman  Keul’s
multiple range test.
            *a Values are significantly different from normal control at P<0.01.
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RESULTS AND DISCUSSION
    SYNTHETIC METHODOLOGY:
   The titled compounds were synthesized in a 3 step process:
 The first step in which Anthranilic acid undergoes cyclization by the treatment with
Pentanoic anhydride to yield 2-butyl-4H-3, 1-benzoxazin-4-one.
 The advantage is that it is an useful intermediate to afford 3-amino-2(n-butyl)-
            quinazolin-(3H)-4one on condensation with Hydrazine hydrate.
 The presence of  active hydrogen in N-3 position facilitates the Mannich reaction to 
take place with several amines to yield 3-substituted amino-2(n-butyl)quinazolin-
(3H)-4-one derivatives.
    Characterization: 
 
 The melting points were found in an open end capillary tube method by electrically
           heating melting point apparatus and are uncorrected.
 The purity of the compounds were analysed by Thin Layer chromatography using 
      Silica Gel (0.5 mm thickness) as stationary phase, employing 
      Methanol:Chloroform:Water (9:1:1) as Mobile phase, spots were visualized using 
      Iodine vapours.
The Rf value of the synthesized compounds were calculated.
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 The  characterization  of  the  titled  compounds  including  Infrared  and  Nuclear
Magnetic Resonance Spectral data were in correlation with the expected structure.
PHARMACOLOGICAL SCREENING:
Anti Convulsant Activity:
 
 Anti Convulsant activity of the synthesized compounds were evaluated by Supra 
Maximal Electrical Shock  Method, because it was the most widely employed 
seizure models for the early identification and high throughput screening of 
investigational Antiepileptic Drugs.
 Compounds A2, A5,A6,A7,A8 and A9 (5mg/Kg) abolished the duration of extensor 
phase when compared to the control and hence they were concluded to possess 
significant Anticonvulsant Activity.
 The standard drug Phenytoin sodium at a dose of 25mg/kg produced drastic 
abolision of extensor phase.
 Compounds like A1,A3,A4 and A10(5mg/kg) does not possess significant 
Anticonvulsant activity when compared to control(Standard Group)
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Analgesic Activity:
 The synthesized compounds were evaluated for Analgesic Activity by Acetic acid 
Induced Writhing Method.
 Maximum degree of Analgesic Activity was observed for compounds A1, A2, A5, 
A8, A9 andA10(5mg/kg). The writhing effect was significantly inhibited by the above
compounds
 The standard drug Diclofenac Sodium at a dose of 10mg/kg inhibited the writhing 
effect to a greater extent.
 Compounds like A3, A4, A6 and A7(5mg/kg) possess moderate analgesic activity 
when compared to standard group.
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    ANTI CONVULSANT ACTIVITY OF VARIOUS SYNTHESIZED DRUGS BY 
SUPRA MAXIMAL ELECTRICAL SHOCK METHOD 
Chart No: I
   EFFECT OF ANALGESIC ACTIVITIES OF SYNTHESIZED COMPOUNDS
                                                       AGAINST ACETIC ACID INDUCED WRITHING 
TESTS IN MICE.
                                                                                                        Chart No: II
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CONCLUSION
• Novel 2-(n-butyl)-3-substituted amino Quinazolin-4(3H)-ones were synthesized by
a 3step process using Anthranilic acid and Pentanoic anhydride as starting materials.
• The Melting points were found for the synthesized compounds and are uncorrected.
The  purity  of  the  synthesized  compounds  were  analysed  by  Thin  Layer
Chromatography methods.
• The structures of the synthesized compounds has been elucidated by  Infrared and
Nuclear Magnetic Resonance Spectroscopy.  
• The anticonvulsant activity of the synthesized compounds (5mg/kg) were screened
by  Supra Maximal Electrical Shock method in Albino Rats against the standard
drug Phenytoin (25mg/kg)
• The result obtained showed that the attachments of diethyl amine,4-bromo aniline,
4-nitro aniline, P-Amino benzoic Acid, Sulphanilamide and Indole moieties to the
Quinazolin- 4(3H)-one ring exhibited significant Anticonvulsant activity.
• Based on the results, the attachment of dimethyl amine, benztriazole to Quinazolin-
4(3H)-one shown to have moderate Anticonvulsant activity while diphenyl amine,
aniline  substituted  Quinazolin-4(3H)-one shown  to  have  less  Anticonvulsant
activity comparatively.
• The  analgesic activity of  the synthesized compounds (5mg/kg)  were screened by
Acetic  Acid  Induced  Writhing  method in  Albino  rats  against  the  standard  drug
Diclofenac sodium(25mg/kg)
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• From  the  obtained  results  Quinazolin-4(3H)-one  ring  having   substitutions  like
Dimethyl  amine,  diethyl  amine,  4-bromoaniline,sulphanilamide,Indole  Benztriazole
showed significant Analgesic Activity while the other groups shows only Moderate
Activity.
• Future investigations can be made to study its Pharmacokinetic parameters, 
potency,efficacy, drug interactions ,side effects of the titled compounds in order to
bring out the novel Quinazoline -4(3H)-one derivatives as a successful drug 
molecules.
• Extended studies can be made to broaden the therapeutic utility of the synthesized 
compounds such as anti microbial, anti malarial, anti tuberculosis, anti 
parkinsonism, anti HIV, anti cancer, anti histaminic, local anaesthetic, anti 
hypertensive and antiviral activities
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